Mylan Laboratories
 |
|
| Mylan N.V. | |
|
Formerly called
|
Milan |
| Public (under Dutch law) | |
| Traded as |
NASDAQ: MYL : MYL NASDAQ Biotechnology Component NASDAQ-100 Component S&P 500 Component |
| ISIN | US6285301072 |
| Industry | Pharmaceuticals |
| Founded | 1961 in White Sulphur Springs, West Virginia, United States |
| Founders |
Milan Puskar Don Panoz |
| Headquarters | Canonsburg, Pennsylvania, United States of America |
|
Area served
|
Worldwide |
|
Key people
|
Heather Bresch, CEO |
| Products | Generic and specialty pharmaceuticals and active pharmaceutical ingredients |
| Revenue |
 US$9.42 billion (2015) |
 US$830.1 million (2015) |
|
|
US$4.216 billion (2015) |
|
| Total assets |
US$ 22.267 billion (2015) |
| Total equity |
US$9.765 billion (2015) |
|
Number of employees
|
~35,000 (2015) |
| Divisions | see Operations |
| Subsidiaries | Meda Famy Care |
| Website | www |
Mylan N.V. is an American global generic and specialty pharmaceuticals company registered in the Netherlands, with principal executive offices in Hatfield, Hertfordshire, UK and global headquarters in Canonsburg, Pennsylvania, US. In 2007, Mylan acquired a controlling interest in India-based Matrix Laboratories Limited, a top producer of active pharmaceutical ingredients (APIs) for generic drugs, and the generics business of Germany-based Merck KGaA. Through these acquisitions, Mylan grew from the third-largest generic and pharmaceuticals company in the United States to the second-largest generic and specialty pharmaceuticals company in the world.
In 2016, Mylan's pricing of the EpiPen, an epinephrine autoinjector, became controversial and was widely referred to as "price gouging". As a result, investigations were opened into whether Mylan had misclassified the EpiPen under the Medicaid Drug Rebate Program, a common form of pharmaceutical fraud. In October 2016, Mylan settled these investigations with the U.S. Department of Justice, agreeing to pay $465 million and enter into a corporate integrity agreement concerning the rebate program. In a report published on June 12, 2017 the Institutional Shareholder Services criticized Mylan for the "outsized compensation" of Mylan's directors. Former CEO Robert Coury received a "$98 million" 2016 "pay package" in spite of the "harm to the company inflicted by the EpiPen controversies" and "steep shareholder losses." The report urged Mylan's shareholders to "oust all of Mylan's existing directors".
Mylan Inc. operates several divisions and subsidiaries:
In North America and South America, Mylan operates:
In Oceania and Central, East, South, and Southeast Asia, Mylan operates:
In Europe, Africa, and West Asia, Mylan operates:
...
Wikipedia